drugset
drugset / Trial / NCT02143050

Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients

NCT02143050 ↗

Phase 1/2 Withdrawn University of Louisville James Graham Brown Cancer Center · collab
NaSingle-groupOpen-labelTreatment

Summary

The main purpose is to evaluate the clinical response, safety and survival of the FDA approved drugs Dabrafenib, Trametinib in combination with Metformin. Investigators hypothesize that the combination of an FDA approved non toxic dose of oral Metformin with the B-Raf inhibitor, Dabrafenib and the MEK inhibitor, Trametinib will yield little toxicity and improve clinical outcomes in terms of objective response rates and survival in metastatic melanoma patients.

Timeline

Start
2014-09
Primary completion
2017-11-17
Completion
2017-11-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabrafenib Small molecule 150 mg Oral
Subject Metformin Small molecule 850 mg Oral
Subject Trametinib Small molecule 2 mg Oral

Indications

melanoma